NanoViricides (NNVC)
XASE:NNVC
Want to see NNVC full AI Analyst Report?
Top Page
NanoViricides
(NYSE MKT:NNVC)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(76.99% Upside)
Action:Reiterated
Date:05/28/26
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and negative cash flow with heightened uncertainty from extreme TTM figures). Technical signals are comparatively supportive with price strength above major moving averages and positive MACD, while valuation remains challenged by losses and no dividend. A positive corporate update provides some upside narrative but is still early-stage.
Positive Factors
Proprietary platform & pipeline
NanoViricides’ nanoviricide platform is a structural competitive asset: it mimics host-cell binding to disrupt viral particles, enabling multiple drug formats (e.g., NV-387 and remdesivir-encapsulated). This platform breadth supports durable pipeline expansion, licensing or partner strategies across viral indications.
Negative Factors
No revenue / pre-commercial profile
NNVC remains pre-commercial with zero reported revenue and persistent net losses. Without commercialized products, the firm lacks internally generated cash flow, making long-term sustainability dependent on successful trials, milestone payments, or continued external financing rather than operating earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform & pipeline
NanoViricides’ nanoviricide platform is a structural competitive asset: it mimics host-cell binding to disrupt viral particles, enabling multiple drug formats (e.g., NV-387 and remdesivir-encapsulated). This platform breadth supports durable pipeline expansion, licensing or partner strategies across viral indications.
Read all positive factors
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$40.26M
Dividend YieldN/A
Average Volume (3M)143.34K
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue GrowthN/A
EPS Growth37.68%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding21,647,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-79.81K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.79M
Enterprise Value/Ebitda424.18K
Forecast
1Y Price Target
$6.00Price Target Upside430.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
NanoViricides Business Overview & Revenue Model
Company Description
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus a...
How the Company Makes Money
null...
NanoViricides Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -129.63K | 0.00 | 0.00 | -747.53K | 0.00 | 0.00 |
| EBITDA | -7.58M | -8.72M | -7.49M | -7.84M | -7.38M | -8.04M |
| Net Income | -8.09M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M |
Balance Sheet | ||||||
| Total Assets | 10.22T | 8.82M | 12.82M | 16.90M | 23.49M | 30.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.21T | 1.56M | 4.80M | 8.15M | 14.07M | 20.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 94.79K | 95.31K |
| Total Liabilities | 1.07T | 1.31M | 1.36M | 2.03M | 412.84K | 351.15K |
| Stockholders Equity | 9.15T | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M |
Cash Flow | ||||||
| Free Cash Flow | -7.37M | -8.54M | -6.47M | -5.82M | -6.22M | -8.45M |
| Operating Cash Flow | -7.28M | -8.48M | -6.32M | -5.67M | -5.89M | -8.21M |
| Investing Cash Flow | -94.52K | -56.96K | -156.56K | -151.71K | -324.35K | -238.76K |
| Financing Cash Flow | 8.04M | 5.30M | 3.12M | -94.79K | -234.72K | 15.26M |
NanoViricides Technical Analysis
Positive
1.13
Price Trends
1.29
Positive
1.17
Positive
1.29
Positive
Market Momentum
0.13
Negative
61.72
Neutral
75.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Positive. The current price of 1.13 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.29, and below the 200-day MA of 1.29, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 61.72 is Neutral, neither overbought nor oversold. The STOCH value of 75.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 51 risk factors in its most recent earnings report. NanoViricides reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NanoViricides Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $40.26M | -4.75 | >-0.01% | ― | ― | 37.68% | |
52 Neutral | $14.62M | -3.79 | ― | ― | ― | 80.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $272.98M | -483.93 | -0.29% | ― | -100.00% | 72.96% | |
48 Neutral | $25.24M | -0.01 | -68.21% | ― | ― | ― | |
44 Neutral | $184.26M | 0.03 | 248.08% | ― | ― | ― |
* Healthcare Sector Average
NNVC
NanoViricides
1.78
0.24
15.58%
ENLV
Enlivex
0.81
-0.13
-13.83%
AKTX
Akari Therapeutics
16.43
-40.17
-70.97%
MBRX
Moleculin Biotech
2.79
-19.96
-87.73%
SABS
SAB Biotherapeutics
3.60
1.68
87.50%
NanoViricides Corporate Events
Business Operations and StrategyProduct-Related Announcements
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak
Positive
May 21, 2026
NanoViricides disclosed that at the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, President and Executive Chairman Dr. Anil R. Diwan outlined how its lead candidate NV-387, along with a remdesivir-encapsulated version, ma...
Business Operations and StrategyPrivate Placements and Financing
NanoViricides Completes $2 Million Registered Direct Offering
Neutral
May 20, 2026
NanoViricides, Inc., a clinical-stage antiviral specialist, entered a securities purchase agreement on May 15, 2026, with a single institutional investor for a registered direct offering of common stock, pre-funded warrants, and common warrants. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.